The GLP

GLP-1 prescriptions have surged 587%. Discover what the data reveals about prescribing trends and how HealthVerity supports post-market research.

Why This Matters Understanding which patients stay on GLP-1s helps organizations better estimate the drugs' real-world effectiveness and cost impact. It also provides a starting point for improving support strategies—whether through targeted education, care management, or benefits design. Just as health systems responded to disparities in statin adherence with outreach and protocol ...
Key Details About The Glp 1 Trend What The Real World Data Reveals

Explore 2025 GLP-1 trends with real-world data on adoption, outcomes & future drugs. See how GLP-1s are reshaping diabetes & obesity care.
The analysis leverages real-world data from Phesi's Trial Accelerator™ platform and a newly published Digital Patient Profile (DPP) of GLP-1 patients. The findings reflect growing interest in GLP-1s as a broader modulatory pathway across multiple indications including cardiovascular disease, polycystic ovary disease, osteoarthritis and ...

Useful Notes on The Glp 1 Trend What The Real World Data Reveals
A 2026 NIDDK workshop study examines how real-world evidence can fill critical gaps in GLP-1 receptor agonist safety, effectiveness, and coverage decisions.
GLP-1 trends in 2025 are reshaping obesity treatment—but real-world outcomes aren't keeping pace with the hype. Clinical trials showed weight reductions between 10-20%, leading to FDA approvals and widespread enthusiasm. Yet in day-to-day practice, those expectations often fall short. A major June 2025 study from the Cleveland Clinic revealed that over half of patients discontinued GLP-1 ...

Overview of The Glp 1 Trend What The Real World Data Reveals
How GLP-1 users are changing consumer spending habits As of May 2026, roughly one in five U.S. households (21%) includes a current GLP-1 user, up from 9% in January 2025, based on PwC analysis of data from Numerator.
Numerator's GLP-1 Trends Hub provides a centralized view of consumer GLP-1 usage and interest alongside purchasing behavior and demographics, now available for Numerator clients.

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP ...
EAGAN, Minn. - Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 ( GLP-1 ) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime). Meanwhile, individuals who took a high-potency GLP-1 drug approved for obesity — such as semaglutide (Wegovy ...








Key GLP-1 Stats • About 12% of U.S. adults report using GLP-1 medications for weight loss • GLP-1 prescriptions for obesity increased nearly 587% between 2019 and 2024 • More than 26% of U.S ...